Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImmunoCellular plummets on ICT-107 Phase II miss

This article was originally published in Scrip

Executive Summary

ImmunoCellular Therapeutics tried to put a positive spin on statistically significant progression-free survival (PFS) for newly-diagnosed glioblastoma multiforme patients treated with the dendritic cell-based cancer vaccine ICT-107 in a Phase II clinical trial, but the company's stock dropped by more than half based on the trial's missed overall survival (OS) primary endpoint.

Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

SC023774

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel